
|Articles|June 20, 2019
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
Author(s)Adi Diab, MD
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Advertisement
Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma
2
FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC
3
Apalutamide Reduces Risk of Death by 51% in Metastatic CSPC
4
FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC
5
































